BDX Stock Overview
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a non-invasive blood test for the detection of breast cancer.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BCAL Diagnostics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.095 |
| 52 Week High | AU$0.21 |
| 52 Week Low | AU$0.07 |
| Beta | 0.27 |
| 1 Month Change | 1.06% |
| 3 Month Change | -4.04% |
| 1 Year Change | 18.75% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -62.00% |
Recent News & Updates
Shareholder Returns
| BDX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -9.5% | 1.9% | 0.9% |
| 1Y | 18.8% | -7.7% | 5.6% |
Return vs Industry: BDX exceeded the Australian Biotechs industry which returned -7.7% over the past year.
Return vs Market: BDX exceeded the Australian Market which returned 5.6% over the past year.
Price Volatility
| BDX volatility | |
|---|---|
| BDX Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: BDX has not had significant price volatility in the past 3 months.
Volatility Over Time: BDX's weekly volatility has decreased from 14% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Shane Ryan | www.bcaldiagnostics.com |
BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a non-invasive blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from patient's blood plasma to diagnose the presence of breast cancer cells in a patient’s body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.
BCAL Diagnostics Limited Fundamentals Summary
| BDX fundamental statistics | |
|---|---|
| Market cap | AU$23.97m |
| Earnings (TTM) | -AU$5.00m |
| Revenue (TTM) | AU$3.71m |
6.5x
P/S Ratio-4.8x
P/E RatioIs BDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BDX income statement (TTM) | |
|---|---|
| Revenue | AU$3.71m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$3.71m |
| Other Expenses | AU$8.70m |
| Earnings | -AU$5.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.02 |
| Gross Margin | 100.00% |
| Net Profit Margin | -134.82% |
| Debt/Equity Ratio | 9.0% |
How did BDX perform over the long term?
See historical performance and comparison